One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).
These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Patients aged ≥18 years.
With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
Who have received at least one of the doses of the study drugs.
In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
Patients in whom more than 50% of the variables to be collected are missing in the data collection.
7
Trial groupsSee each trial group below.